Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent…
WATERTOWN, Mass., June 09, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to…